Related Experiment Video

Updated: Sep 23, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer

Theodora A Constantin1, Kyle K Greenland1, Anabel Varela-Carver1

  • 1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Oncogene
|May 14, 2022
PubMed

Insights

Transcription-associated cyclin-dependent kinases (tCDKs) are key targets in prostate cancer therapy. Inhibiting tCDKs shows promise for treating metastatic castration-resistant prostate cancer by blocking oncogenic gene transcription.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Transcriptional deregulation is a key feature in many cancers, including prostate cancer.
  • Metastatic castration-resistant prostate cancer (mCRPC) often maintains dependence on androgen receptor signaling.
  • Current therapies for mCRPC face limitations, necessitating novel treatment strategies.

Purpose of the Study:

  • To summarize the role of transcription-associated cyclin-dependent kinases (tCDKs) in gene transcription.
  • To highlight the rationale for targeting tCDKs in prostate cancer treatment.
  • To review recent clinical advances and combination strategies involving tCDK inhibitors.

Main Methods:

  • Review of preclinical studies on tCDK function and inhibition.
  • Analysis of the therapeutic potential of selective tCDK inhibitors.
  • Overview of current clinical trials and combination therapies in prostate cancer.

Main Results:

  • Transcription-associated cyclin-dependent kinases (tCDKs) are identified as druggable targets.
  • Selective inhibition of tCDKs demonstrates potential for anti-tumor effects with a therapeutic window.
  • Several specific tCDK inhibitors are undergoing clinical trials for solid tumors, including prostate cancer.

Conclusions:

  • Targeting tCDKs offers a promising therapeutic strategy for prostate cancer, particularly mCRPC.
  • tCDK inhibitors may provide anti-tumor effects without significant systemic toxicity.
  • Combination therapies involving tCDK inhibitors and established agents warrant further investigation.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

8.8K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K